About Sunshine Biopharma Inc
Ticker
info
SBFM
Trading on
info
NASDAQ
ISIN
info
US8677814035
Industry
info
Drug Manufacturers - Specialty & Generic
Sector
info
Healthcare
CEO
info
Dr. Steve N. Slilaty Ph.D.
Headquarters
info
333 Las Olas Way, Fort Lauderdale, FL, United States, 33301
Employees
info
52
Website
info
https://sunshinebiopharma.com
Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
Metrics
BasicAdvanced
Market cap
info
$8.2M
P/E ratio
info
-
EPS
info
-$15.02
Dividend Yield
info
0.00%
Beta
info
0.73
Forward P/E ratio
info
0
EBIDTA
info
$-5.2M
Ex dividend date
info
-
Price & volume
Market cap
info
$8.2M
Average daily volume
info
0.1M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
0
Trailing P/E
info
0
Price to sales
info
0.19
Price to book
info
0.3
Earnings
EPS
info
-$15.02
EPS estimate (current quarter)
info
$0.00
EPS estimate (next quarter)
info
$0.00
EBITDA
info
$-5.2M
Revenues (TTM)
info
$36.3M
Revenues per share (TTM)
info
$14.63
Technicals
Beta
info
0.73
52-week High
info
$3.59
52-week Low
info
$1.17
50-day moving average
info
$1.65
200-day moving average
info
$1.70
Short ratio
info
0.5
Short %
info
18.78%
Management effectiveness
ROE (TTM)
info
-25.65%
ROA (TTM)
info
-11.08%
Profit margin
info
-17.35%
Gross profit margin
info
$12.1M
Operating margin
info
-10.55%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
1.20%
Share stats
Outstanding Shares
info
4.9M
Float
info
4.6M
Insiders %
info
2.94%
Institutions %
info
2.61%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 1 analysts.

Average price target

info
$7.00
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.94
-$535.00
99.82%
Q3 • 24Beat
-
$0.01
-
Q4 • 24Beat
-$0.84
$0.07
-1,295.00%
Q1 • 25Missed
-$0.39
-$0.11
-254.55%
Q2 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$9.4M
$-1.8M
-18.82%
Q2 • 25
$9.4M
$-0.9M
-9.39%
Q3 • 25
0.07%
-50.09%
-50.13%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$32M
$6.3M
19.65%
Q2 • 25
$31.5M
$7.3M
23.15%
Q3 • 25
-1.49%
16.04%
17.80%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-1.3M
$-0.5M
$3.6M
$-1.8M
Q2 • 25
$-0.7M
$-0.1M
$0.1M
$-0.8M
Q3 • 25
-42.85%
-75.95%
-97.91%
-58.22%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Sunshine Biopharma Inc share?
Collapse

Sunshine Biopharma Inc shares are currently traded for undefined per share.

How many shares does Sunshine Biopharma Inc have?
Collapse

Sunshine Biopharma Inc currently has 4.9M shares.

Does Sunshine Biopharma Inc pay dividends?
Collapse

No, Sunshine Biopharma Inc doesn't pay dividends.

What is Sunshine Biopharma Inc 52 week high?
Collapse

Sunshine Biopharma Inc 52 week high is $3.59.

What is Sunshine Biopharma Inc 52 week low?
Collapse

Sunshine Biopharma Inc 52 week low is $1.17.

What is the 200-day moving average of Sunshine Biopharma Inc?
Collapse

Sunshine Biopharma Inc 200-day moving average is $1.70.

Who is Sunshine Biopharma Inc CEO?
Collapse

The CEO of Sunshine Biopharma Inc is Dr. Steve N. Slilaty Ph.D..

How many employees Sunshine Biopharma Inc has?
Collapse

Sunshine Biopharma Inc has 52 employees.

What is the market cap of Sunshine Biopharma Inc?
Collapse

The market cap of Sunshine Biopharma Inc is $8.2M.

What is the P/E of Sunshine Biopharma Inc?
Collapse

The current P/E of Sunshine Biopharma Inc is null.

What is the EPS of Sunshine Biopharma Inc?
Collapse

The EPS of Sunshine Biopharma Inc is -$15.02.

What is the PEG Ratio of Sunshine Biopharma Inc?
Collapse

The PEG Ratio of Sunshine Biopharma Inc is 0.

What do analysts say about Sunshine Biopharma Inc?
Collapse

According to the analysts Sunshine Biopharma Inc is considered a buy.